Report workspace tools

NCT05253534COMPLETEDanonymous

Pilot Study to Evaluate Clinically the Short-Term Efficacy of GlaucoT Glaucoma Treatment Glasses in the Treatment of Primary Open-Angle Glaucoma (GlaucoT)

Sponsor

Source record

Glaucot Teknoloji Anonim Sirketi

Phase

Source record

Pilot Study

Modality

AI-normalized

medical device

Target

AI-normalized

Flicker light therapy targeting neuroprotection and retinal ganglion cell preservation in primary open-angle glaucoma (POAG).

Indication / condition

AI-normalized

Primary Open-Angle Glaucoma

Intervention

Source record

GlaucoT Glaucoma Treatment Device

Source & freshness

Source record

NCT ID

NCT05253534

Original source

ClinicalTrials.gov

Source last updated

Nov 18, 2024

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05253534

Title

Pilot Study to Evaluate Clinically the Short-Term Efficacy of GlaucoT Glaucoma Treatment Glasses in the Treatment of Primary Open-Angle Glaucoma (GlaucoT)

Sponsor

Glaucot Teknoloji Anonim Sirketi

Status

COMPLETED

Phase

Pilot Study

Condition raw

Primary Open-Angle Glaucoma

Condition normalized

Primary Open-Angle Glaucoma

Modality raw

medical device

Modality normalized

medical device

Target raw

Flicker light therapy targeting neuroprotection and retinal ganglion cell preservation in primary open-angle glaucoma (POAG).

Target normalized

Flicker light therapy targeting neuroprotection and retinal ganglion cell preservation in primary open-angle glaucoma (POAG).

Interventions

GlaucoT Glaucoma Treatment Device

Public preview

Source record

Glaucot Teknoloji Anonim Sirketi's GlaucoT glasses represent an innovative approach to treating POAG by utilizing flicker light therapy, which has shown promise in neuroprotection. Given the increasing prevalence of glaucoma, projected to affect over 60 million individuals globally, this device could address a significant unmet need in the market. The competitive landscape includes traditional IOP-lowering medications and surgical interventions, but GlaucoT's non-invasive, cost-effective solution may appeal to patients seeking alternatives. Successful outcomes could position Glaucot as a leader in glaucoma management, potentially leading to partnerships or licensing opportunities within the ophthalmic device sector.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account

Create a free account first, then unlock a single report, buy credits or subscribe.